Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 2/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13291061 | 0.85 | ENPP3 (0.62) | ENPP3ENPP1HSD17B1HSD17B2NOTUM | |
| SCHEMBL1608482 | 0.85 | ENPP3 (0.69) | ENPP3ENPP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3034992 | 0.84 | ENPP3 (0.60) | ENPP3ENPP1HSD17B1HSD17B2NOTUM | |
| SCHEMBL1177949 | 0.82 | ENPP3 (0.74) | ENPP3ENPP1HSD17B1HSD17B2NOTUM | |
| SCHEMBL1250845 | 0.79 | KDM4E (0.73) | NOTUMSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL14266224 | 0.77 | ABL1 (0.55) | HSD17B2ALDH1A1TDP1MAPTLMNA | |
| SCHEMBL12171824 | 0.76 | VDR (0.55) | ENPP3ENPP1NOTUMSMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL10429250 | 0.76 | ENPP3 (0.44) | ENPP3ENPP1HSD17B1HSD17B2NPC1 | |
| SCHEMBL4193013 | 0.75 | NPC1 (0.65) | ENPP3ENPP1NOTUMSMN1; SMN2NPC1 | |
| SCHEMBL3506902 | 0.75 | PDE4B (0.57) | ENPP3ENPP1NOTUMSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2023919-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | Molecular Neuroimaging, LLC (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008118122-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118122-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | APP, BACE1, BACE2 | ENPP3 915/4885ENPP1 1151/4885HSD17B1 289/4885 |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | ENPP3 915/4885ENPP1 1151/4885HSD17B1 289/4885 |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | ENPP3 915/4885ENPP1 1151/4885HSD17B1 289/4885 |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | ENPP3 915/4885ENPP1 1151/4885HSD17B1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.